Global Drugs for Vulvovaginal Candidiasis Market by Manufacturers, Countries, Type and Application, Forecast to 2023

Publisher Name :
Date: 08-Mar-2018
No. of pages: 109

The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Scope of the Report:

This report focuses on the Drugs for Vulvovaginal Candidiasis in global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, types and applications.

Market Segment by Manufacturers, this report covers

- Bayer

- Perrigo

- J & J

- Pfizer

- Bristol-Myers Squibb

- Effik

- Teva

- Sanofi

- Cisen Pharmaceutical

- Kingyork Group

Market Segment by Regions, regional analysis covers

- North America (United States, Canada and Mexico)

- Europe (Germany, France, UK, Russia and Italy)

- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

- South America (Brazil, Argentina, Colombia)

- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

- Miconazole

- Clotrimazole

- Fluconazole

- Econazole

- Other

Market Segment by Applications, can be divided into

- Hospital & Clinic

- Pharmacy

There are 15 Chapters to deeply display the global Drugs for Vulvovaginal Candidiasis market.

Chapter 1, to describe Drugs for Vulvovaginal Candidiasis Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Drugs for Vulvovaginal Candidiasis, with sales, revenue, and price of Drugs for Vulvovaginal Candidiasis, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Drugs for Vulvovaginal Candidiasis, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Drugs for Vulvovaginal Candidiasis market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Drugs for Vulvovaginal Candidiasis sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Global Drugs for Vulvovaginal Candidiasis Market by Manufacturers, Countries, Type and Application, Forecast to 2023

Table of Contents

1 Market Overview
1.1 Drugs for Vulvovaginal Candidiasis Introduction
1.2 Market Analysis by Type
1.2.1 Miconazole
1.2.2 Clotrimazole
1.2.3 Fluconazole
1.2.4 Econazole
1.2.5 Other
1.3 Market Analysis by Applications
1.3.1 Hospital & Clinic
1.3.2 Pharmacy
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market Status and Outlook (2013-2023)
1.4.1.2 Canada Market Status and Outlook (2013-2023)
1.4.1.3 Mexico Market Status and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market Status and Outlook (2013-2023)
1.4.2.2 France Market Status and Outlook (2013-2023)
1.4.2.3 UK Market Status and Outlook (2013-2023)
1.4.2.4 Russia Market Status and Outlook (2013-2023)
1.4.2.5 Italy Market Status and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market Status and Outlook (2013-2023)
1.4.3.2 Japan Market Status and Outlook (2013-2023)
1.4.3.3 Korea Market Status and Outlook (2013-2023)
1.4.3.4 India Market Status and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market Status and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market Status and Outlook (2013-2023)
1.4.4.2 Egypt Market Status and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market Status and Outlook (2013-2023)
1.4.4.4 South Africa Market Status and Outlook (2013-2023)
1.4.4.5 Nigeria Market Status and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Bayer
2.1.1 Business Overview
2.1.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Perrigo
2.2.1 Business Overview
2.2.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 J & J
2.3.1 Business Overview
2.3.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb
2.5.1 Business Overview
2.5.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Effik
2.6.1 Business Overview
2.6.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Teva
2.7.1 Business Overview
2.7.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.7.2.1 Type 1
2.7.2.2 Type 2
2.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sanofi
2.8.1 Business Overview
2.8.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.8.2.1 Type 1
2.8.2.2 Type 2
2.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Cisen Pharmaceutical
2.9.1 Business Overview
2.9.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.9.2.1 Type 1
2.9.2.2 Type 2
2.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Kingyork Group
2.10.1 Business Overview
2.10.2 Drugs for Vulvovaginal Candidiasis Type and Applications
2.10.2.1 Type 1
2.10.2.2 Type 2
2.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share
3.3.2 Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer Market Share
3.4 Market Competition Trend
4 Global Drugs for Vulvovaginal Candidiasis Market Analysis by Regions
4.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Regions
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Regions (2013-2018)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Regions (2013-2018)
4.2 North America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
4.3 Europe Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
4.5 South America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
5 North America Drugs for Vulvovaginal Candidiasis by Countries
5.1 North America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
5.1.1 North America Drugs for Vulvovaginal Candidiasis Sales and Market Share by Countries (2013-2018)
5.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Countries (2013-2018)
5.2 United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
5.3 Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
5.4 Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6 Europe Drugs for Vulvovaginal Candidiasis by Countries
6.1 Europe Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
6.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Countries (2013-2018)
6.2 Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.3 UK Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.4 France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.5 Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
6.6 Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7 Asia-Pacific Drugs for Vulvovaginal Candidiasis by Countries
7.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Countries (2013-2018)
7.2 China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.3 Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.4 Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.5 India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
8 South America Drugs for Vulvovaginal Candidiasis by Countries
8.1 South America Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
8.1.1 South America Drugs for Vulvovaginal Candidiasis Sales and Market Share by Countries (2013-2018)
8.1.2 South America Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
8.3 Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
8.4 Colombia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9 Middle East and Africa Drugs for Vulvovaginal Candidiasis by Countries
9.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.3 UAE Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.4 Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.5 Nigeria Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
9.6 South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
10 Global Drugs for Vulvovaginal Candidiasis Market Segment by Type
10.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Drugs for Vulvovaginal Candidiasis Sales and Market Share by Type (2013-2018)
10.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue and Market Share by Type (2013-2018)
10.2 Miconazole Sales Growth and Price
10.2.1 Global Miconazole Sales Growth (2013-2018)
10.2.2 Global Miconazole Price (2013-2018)
10.3 Clotrimazole Sales Growth and Price
10.3.1 Global Clotrimazole Sales Growth (2013-2018)
10.3.2 Global Clotrimazole Price (2013-2018)
10.4 Fluconazole Sales Growth and Price
10.4.1 Global Fluconazole Sales Growth (2013-2018)
10.4.2 Global Fluconazole Price (2013-2018)
10.5 Econazole Sales Growth and Price
10.5.1 Global Econazole Sales Growth (2013-2018)
10.5.2 Global Econazole Price (2013-2018)
10.6 Other Sales Growth and Price
10.6.1 Global Other Sales Growth (2013-2018)
10.6.2 Global Other Price (2013-2018)
11 Global Drugs for Vulvovaginal Candidiasis Market Segment by Application
11.1 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
11.2 Hospital & Clinic Sales Growth (2013-2018)
11.3 Pharmacy Sales Growth (2013-2018)
12 Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.1 Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2018-2023)
12.2 Drugs for Vulvovaginal Candidiasis Market Forecast by Regions (2018-2023)
12.2.1 North America Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.2 Europe Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.3 Asia-Pacific Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.4 South America Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.2.5 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
12.3 Drugs for Vulvovaginal Candidiasis Market Forecast by Type (2018-2023)
12.3.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2018-2023)
12.3.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2018-2023)
12.4 Drugs for Vulvovaginal Candidiasis Market Forecast by Application (2018-2023)
12.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2018-2023)
12.4.2 Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source

List of Tables and Figures

Figure Drugs for Vulvovaginal Candidiasis Picture
Table Product Specifications of Drugs for Vulvovaginal Candidiasis
Figure Global Sales Market Share of Drugs for Vulvovaginal Candidiasis by Types in 2017
Table Drugs for Vulvovaginal Candidiasis Types for Major Manufacturers
Figure Miconazole Picture
Figure Clotrimazole Picture
Figure Fluconazole Picture
Figure Econazole Picture
Figure Other Picture
Figure Drugs for Vulvovaginal Candidiasis Sales Market Share by Applications in 2017
Figure Hospital & Clinic Picture
Figure Pharmacy Picture
Figure United States Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure France Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure UK Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure China Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure India Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Drugs for Vulvovaginal Candidiasis Revenue (Value) and Growth Rate (2013-2023)
Table Bayer Basic Information, Manufacturing Base and Competitors
Table Bayer Drugs for Vulvovaginal Candidiasis Type and Applications
Table Bayer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Perrigo Basic Information, Manufacturing Base and Competitors
Table Perrigo Drugs for Vulvovaginal Candidiasis Type and Applications
Table Perrigo Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table J & J Basic Information, Manufacturing Base and Competitors
Table J & J Drugs for Vulvovaginal Candidiasis Type and Applications
Table J & J Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Pfizer Basic Information, Manufacturing Base and Competitors
Table Pfizer Drugs for Vulvovaginal Candidiasis Type and Applications
Table Pfizer Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Type and Applications
Table Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Effik Basic Information, Manufacturing Base and Competitors
Table Effik Drugs for Vulvovaginal Candidiasis Type and Applications
Table Effik Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Teva Basic Information, Manufacturing Base and Competitors
Table Teva Drugs for Vulvovaginal Candidiasis Type and Applications
Table Teva Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Sanofi Basic Information, Manufacturing Base and Competitors
Table Sanofi Drugs for Vulvovaginal Candidiasis Type and Applications
Table Sanofi Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Cisen Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Type and Applications
Table Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Kingyork Group Basic Information, Manufacturing Base and Competitors
Table Kingyork Group Drugs for Vulvovaginal Candidiasis Type and Applications
Table Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Table Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2017)
Figure Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2016
Figure Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer in 2017
Table Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturer (2016-2017)
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2016
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Manufacturer in 2017
Figure Top 3 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Drugs for Vulvovaginal Candidiasis Manufacturer (Revenue) Market Share in 2017
Figure Global Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales by Regions (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Regions (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Revenue by Regions (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Regions in 2013
Figure Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Regions in 2017
Figure North America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2013
Figure North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2017
Table North America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Table North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2013
Figure North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure United States Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Canada Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Mexico Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Europe Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Table Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2013
Table Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure Germany Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure UK Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure France Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Russia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Italy Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries 2017
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Table Asia-Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries 2017
Figure China Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Japan Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Korea Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure India Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Southeast Asia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2017
Table South America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Table South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
Figure South America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure Brazil Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Argentina Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Colombia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue and Growth Rate (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Countries in 2017
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2018)
Table Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries (2013-2018)
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2013
Figure Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Countries in 2017
Figure Saudi Arabia Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure UAE Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Egypt Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure Nigeria Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Figure South Africa Drugs for Vulvovaginal Candidiasis Sales and Growth Rate (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2013-2018)
Figure Global Miconazole Sales Growth (2013-2018)
Figure Global Miconazole Price (2013-2018)
Figure Global Clotrimazole Sales Growth (2013-2018)
Figure Global Clotrimazole Price (2013-2018)
Figure Global Fluconazole Sales Growth (2013-2018)
Figure Global Fluconazole Price (2013-2018)
Figure Global Econazole Sales Growth (2013-2018)
Figure Global Econazole Price (2013-2018)
Figure Global Other Sales Growth (2013-2018)
Figure Global Other Price (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales by Application (2013-2018)
Table Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2013-2018)
Figure Global Hospital & Clinic Sales Growth (2013-2018)
Figure Global Pharmacy Sales Growth (2013-2018)
Figure Global Drugs for Vulvovaginal Candidiasis Sales, Revenue and Growth Rate (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Regions (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Regions (2018-2023)
Figure North America Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
Figure Europe Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
Figure Asia-Pacific Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
Figure South America Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
Figure Middle East and Africa Sales Drugs for Vulvovaginal Candidiasis Market Forecast (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Type (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2018-2023)
Table Global Drugs for Vulvovaginal Candidiasis Market Share Forecast by Application (2018-2023)
Table Distributors/Traders/ Dealers List
  • 2018-2023 India Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 16-Aug-2018        Price: US 3360 Onwards        Pages: 84
    In 2017, the Bacterial Vaginosis Drug market size was xx million USD in India, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In India market, the top players include - Pfizer - Teva - Perrigo - Mylan - Lupin Pharmaceuticals - Prasco - West-Ward - Edenvridge Split by product types/category, covering - Clindamycin - Metronidazole - Tinidazole - Other......
  • Global and India Postmenopausal Vaginal Atrophy Treatment Market Research by Company, Type & Application 2013-2025
    Published: 16-Aug-2018        Price: US 2000 Onwards        Pages: 105
    Summary Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase. Market Segment as follows: By Type - Creams - Tablets - Patches......
  • 2018-2023 Philippines Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 16-Aug-2018        Price: US 3360 Onwards        Pages: 84
    In 2017, the Bacterial Vaginosis Drug market size was xx million USD in Philippines, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In Philippines market, the top players include - Pfizer - Teva - Perrigo - Mylan - Lupin Pharmaceuticals - Prasco - West-Ward - Edenvridge Split by product types/category, covering - Clindamycin - Metronidazole - Tinidazole......
  • 2018-2023 UK Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 16-Aug-2018        Price: US 3360 Onwards        Pages: 84
    In 2017, the Bacterial Vaginosis Drug market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In UK market, the top players include - Pfizer - Teva - Perrigo - Mylan - Lupin Pharmaceuticals - Prasco - West-Ward - Edenvridge Split by product types/category, covering - Clindamycin - Metronidazole - Tinidazole - Other ......
  • 2018-2023 United States Bacterial Vaginosis Drug Market Report (Status and Outlook)
    Published: 16-Aug-2018        Price: US 3360 Onwards        Pages: 84
    In 2017, the Bacterial Vaginosis Drug market size was xx million USD in United States, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023. In United States market, the top players include - Pfizer - Teva - Perrigo - Mylan - Lupin Pharmaceuticals - Prasco - West-Ward - Edenvridge Split by product types/category, covering - Clindamycin - Metronidazole - Tinidazole......
  • Vulvovaginal Candidiasis - Market Insights, Epidemiology and Market Forecast - 2027
    Published: 03-Aug-2018        Price: US 6250 Onwards        Pages: 120
    DelveInsight's ‘Vulvovaginal Candidiasis - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Vulvovaginal Candidiasis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size......
  • Global Drugs for Vulvovaginal Candidiasis Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 02-Aug-2018        Price: US 3480 Onwards        Pages: 131
    The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Drugs for Vulvovaginal Candidiasis Market 2018, Forecast to 2023
    Published: 02-Aug-2018        Price: US 4880 Onwards        Pages: 136
    The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after ......
  • 2018-2023 Global Drugs for Vulvovaginal Candidiasis Consumption Market Report
    Published: 02-Aug-2018        Price: US 4660 Onwards        Pages: 131
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Drugs for Vulvovaginal Candidiasis market for 2018-2023. The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs